Abeona’s ZEVASKYN launch creates high asymmetric upside, but manufacturing yields and QTC conversion must improve before the $16.47 probability-weighted five-year target is de-risked.
Overview
Abeona is a commercial-stage rare-disease cell-therapy company built around ZEVASKYN, an FDA-approved autologous COL7A1 gene-corrected skin-sheet therapy for severe RDEB. It sells patient-specific treatments through specialized U.S. QTCs at approximately $2.85 million–$2.90 million each, targeting an estimated 750 moderate-to-severe patients and a U.S. TAM above $2.1 billion. **The core investment case is a transition from launch losses to operating leverage:** Q2 2026 product revenue reached $11.38 million, up 30.5% sequentially, while management expects gross margin to expand from 63.3% toward 85%–90% as Cleveland manufacturing overhead is absorbed. However, Q2 revenue missed consensus by $0.86 million and EPS missed by $0.12 because one of five treated patients failed to generate recognized revenue due to low manufacturing yield. Cash and investments were $146.83 million against $15.0 million of debt, but 1H operating cash burn was $37.3 million. **The principal near-term catalyst is CMS NTAP implementation on October 1, 2026**, followed by QTC expansion and a target cadence above 3.5 treatments monthly, equivalent to approximately $100 million annual revenue and corporate cash-flow breakeven. At $5.60, Abeona’s EV is approximately $188.5 million and forward P/S is 6.3x FY2026 and 2.9x FY2027 revenue. ABO-701 and out-licensed ABO-102 provide additional optionality.